This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Imojev

Sanofi

Drug Names(s): ChimeriVax-JE

Description: ChimeriVax-JE is derived from the live, attenuated 17D strain of the yellow fever virus, which is the basis for existing yellow fever vaccines.

Deal Structure: In Feburary 2007, sanofi pasteur, the vaccines business of the sanofi-aventis Group, entered into an agreement with Acambis to license ChimeriVax-JE in endemic countries of Asia Pacific, including Thailand, the Philippines, Malaysia, Indonesia, China, Japan, and parts of Australia. Acambis has granted sanofi pasteur marketing, distribution and certain manufacturing rights to ChimeriVax-JE worldwide excluding India and the Indian subcontinent, and the U.S. for which sanofi pasteur has an option. Acambis will receive upfront and milestone payments totaling up to 30 million following marketing authorization of ChimeriVax-JE in key endemic countries and in the European Union. In addition, Acambis will receive royalties on sales and payment for the supply of bulk ChimeriVax-JE product.

In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The...See full deal structure in Biomedtracker


Imojev News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug